The deal, which is expected to close in Q4 2024, includes UCB’s neurology portfolio (Keppra, Vimpat, Neupro) and allergy medicines (Zyrtec, Xyzal)
The firm plans to use the proceeds to fund acquisitions and business development of innovative assets in the pipeline